MX2019006467A - Composiciones y métodos para mejorar la expresión génica. - Google Patents
Composiciones y métodos para mejorar la expresión génica.Info
- Publication number
- MX2019006467A MX2019006467A MX2019006467A MX2019006467A MX2019006467A MX 2019006467 A MX2019006467 A MX 2019006467A MX 2019006467 A MX2019006467 A MX 2019006467A MX 2019006467 A MX2019006467 A MX 2019006467A MX 2019006467 A MX2019006467 A MX 2019006467A
- Authority
- MX
- Mexico
- Prior art keywords
- gene expression
- compositions
- methods
- viral capsid
- improve gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00041—Use of virus, viral particle or viral elements as a vector
- C12N2770/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36061—Methods of inactivation or attenuation
- C12N2770/36062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430250P | 2016-12-05 | 2016-12-05 | |
| US201762486361P | 2017-04-17 | 2017-04-17 | |
| US201762587954P | 2017-11-17 | 2017-11-17 | |
| PCT/US2017/064561 WO2018106615A2 (en) | 2016-12-05 | 2017-12-04 | Compositions and methods for enhancing gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006467A true MX2019006467A (es) | 2019-12-09 |
Family
ID=61157280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006467A MX2019006467A (es) | 2016-12-05 | 2017-12-04 | Composiciones y métodos para mejorar la expresión génica. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11845939B2 (OSRAM) |
| EP (1) | EP3548625B1 (OSRAM) |
| JP (2) | JP7788787B2 (OSRAM) |
| KR (1) | KR102655641B1 (OSRAM) |
| CN (1) | CN110352247B (OSRAM) |
| AU (1) | AU2017372731B2 (OSRAM) |
| BR (1) | BR112019011661A2 (OSRAM) |
| CA (1) | CA3045650A1 (OSRAM) |
| MX (1) | MX2019006467A (OSRAM) |
| WO (1) | WO2018106615A2 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443107A1 (en) | 2016-04-13 | 2019-02-20 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| WO2018075235A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| BR112020014525A2 (pt) | 2018-01-19 | 2020-12-08 | Janssen Pharmaceuticals, Inc. | Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes |
| AU2019222560B2 (en) | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| MX2021004032A (es) | 2018-10-08 | 2021-07-06 | Janssen Pharmaceuticals Inc | Replicones basados en alfavirus para la administracion de bioterapeuticos. |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020181058A1 (en) * | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
| GB201908729D0 (en) * | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| US20220313815A1 (en) * | 2019-06-20 | 2022-10-06 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| CN214973877U (zh) | 2019-08-09 | 2021-12-03 | 胡桃钳医疗公司 | 用于形成治疗性多核苷酸的微流体设备及微流体路径装置 |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| AU2020417800A1 (en) | 2019-12-31 | 2022-07-14 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| US11744887B2 (en) | 2020-03-09 | 2023-09-05 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| EP4135757A1 (en) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| CA3183500A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| BR112022022942A2 (pt) | 2020-05-11 | 2022-12-13 | Janssen Pharmaceuticals Inc | Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4178613A1 (en) | 2020-07-08 | 2023-05-17 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| AU2021325945A1 (en) | 2020-08-14 | 2023-04-06 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| CN112029781B (zh) * | 2020-08-14 | 2023-01-03 | 中山大学 | 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用 |
| GB202020063D0 (en) * | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| GB202020061D0 (en) * | 2020-12-17 | 2021-02-03 | Imp College Innovations Ltd | RNA construct |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| WO2022232687A1 (en) * | 2021-04-30 | 2022-11-03 | Greenlight Biosciences, Inc. | Messenger rna therapeutics and compositions |
| TW202313967A (zh) * | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
| GEAP202516650A (en) | 2022-05-12 | 2025-03-10 | Msd Int Business Gmbh | Stabilized pre-fusion hmpv fusion proteins |
| EP4587048A1 (en) | 2022-09-14 | 2025-07-23 | Ceva Santé Animale | Treatment of atopic dermatitis using self-replicating rna expressing il-31 |
| WO2024139837A1 (en) * | 2022-12-27 | 2024-07-04 | Yu Chien Hung | Recombinant nucleic acids, kits comprising the same, and uses thereof in treating coronavirus infection |
| WO2024259214A1 (en) | 2023-06-14 | 2024-12-19 | Ceva Sante Animale | Self-amplifying rna expressing one or more infectious laryngotracheitis virus ( ilt) antigens |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4738927A (en) | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| EP0446283A4 (en) | 1988-12-01 | 1992-01-08 | Univ North Carolina | Synthetic interleukin-6 |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| AU702367B2 (en) | 1993-08-02 | 1999-02-18 | Scripps Research Institute, The | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| SE9401709D0 (sv) * | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
| DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
| JP2002507985A (ja) | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 横紋筋に核酸を導入する改良法およびその組合せ |
| US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
| US20020164585A1 (en) * | 1998-01-16 | 2002-11-07 | Sean Chapman | Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| IL147343A0 (en) * | 1999-07-21 | 2002-08-14 | Large Scale Biology Corp | Method for enhancing ran or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids |
| US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
| WO2002020721A2 (en) * | 2000-09-07 | 2002-03-14 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
| EP1195438A1 (en) * | 2000-10-06 | 2002-04-10 | Rijksuniversiteit te Groningen | Genetic immunisation against cervical carcinoma |
| AU3163902A (en) | 2000-11-23 | 2002-06-03 | Bavarian Nordic Res Inst As | Modified vaccinia ankara virus variant |
| AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| EP1397498A1 (en) | 2001-05-21 | 2004-03-17 | ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. | Delections in arterivirus replicons |
| ATE354260T1 (de) | 2001-07-19 | 2007-03-15 | Ericsson Telefon Ab L M | Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort |
| US7204997B2 (en) | 2002-01-29 | 2007-04-17 | Supratek Pharma Inc. | Responsive microgel and methods related thereto |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| AU2003297860A1 (en) * | 2002-12-12 | 2004-07-09 | The Board Of Regents Of The University Of Texas System | Large scale production of packaged alphavirus replicons |
| EP1593738A4 (en) * | 2003-01-30 | 2006-05-31 | Shanghai Tengen Biomedical Co | VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| WO2005026316A2 (en) * | 2003-09-15 | 2005-03-24 | Bioption Ab | Alphavirus vaccines |
| US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| NZ550342A (en) | 2004-03-08 | 2010-06-25 | Ichor Medical Systems Inc | Improved apparatus for electrically mediated delivery of therapeutic agents |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| KR100872840B1 (ko) * | 2004-07-09 | 2008-12-22 | (주)씨아이디 | 돼지생식기호흡기증후군 바이러스에 대한 전체-길이의감염성이 있는 cDNA 클론 및 이의 용도 |
| CA2572921C (en) * | 2004-07-09 | 2017-01-03 | The University Of North Carolina At Chapel Hill | Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants |
| JP2009511636A (ja) | 2005-10-18 | 2009-03-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | アルファウイルスレプリコン粒子による粘膜免疫および全身免疫 |
| EP1792996A1 (en) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
| US8859198B2 (en) | 2006-06-06 | 2014-10-14 | Abl Sa | Detection and use of antiviral resistance mutations |
| EP2062246A4 (en) | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| US9452285B2 (en) | 2006-10-17 | 2016-09-27 | Vgx Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
| US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| PL2183368T3 (pl) | 2007-06-21 | 2016-12-30 | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych | |
| WO2009056535A2 (en) | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
| WO2011082388A2 (en) * | 2009-12-31 | 2011-07-07 | Medigen, Inc . | Infectious dna vaccines against chikungunya virus |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| EP2655621B1 (en) | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| ES2806263T3 (es) | 2011-02-11 | 2021-02-17 | Univ Pennsylvania | Molécula de ácido nucleico que codifica la proteína del núcleo del virus de la hepatitis b y vacuna que comprende la misma |
| CN103687644B (zh) | 2011-06-28 | 2016-11-09 | 艾诺奥医药品有限公司 | 微创性皮肤电穿孔装置 |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| WO2013120499A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| EP3348645B1 (en) * | 2012-02-15 | 2020-06-03 | CureVac AG | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP2932993B1 (en) | 2012-12-13 | 2017-03-29 | Panasonic Healthcare Holdings Co., Ltd. | Medicament injection device |
| WO2014170493A2 (en) | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| US20170151339A1 (en) | 2014-06-30 | 2017-06-01 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| CA2962799A1 (en) | 2014-10-01 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
| PT3280729T (pt) * | 2015-04-08 | 2022-08-01 | Novartis Ag | Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19 |
| ES2875589T3 (es) | 2015-05-15 | 2021-11-10 | Curevac Ag | Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm |
| AU2016302237B2 (en) | 2015-08-03 | 2022-08-04 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| SG11201808236YA (en) | 2016-03-28 | 2018-10-30 | Ichor Medical Systems Inc | Method and apparatus for delivery of therapeutic agents |
| US11324819B2 (en) | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
| EP3443107A1 (en) | 2016-04-13 | 2019-02-20 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| WO2018075235A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| JP6613399B2 (ja) | 2017-06-05 | 2019-12-04 | 株式会社ビークル | Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子 |
| CN111542340B (zh) | 2017-11-16 | 2023-12-19 | 华盛顿大学 | 治疗性乙型肝炎病毒(hbv)疫苗 |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| CN111836641A (zh) | 2017-12-19 | 2020-10-27 | 杨森科学爱尔兰无限公司 | 乙型肝炎病毒(hbv)疫苗及其用途 |
-
2017
- 2017-12-04 EP EP17838102.6A patent/EP3548625B1/en active Active
- 2017-12-04 MX MX2019006467A patent/MX2019006467A/es unknown
- 2017-12-04 US US15/831,230 patent/US11845939B2/en active Active
- 2017-12-04 JP JP2019529995A patent/JP7788787B2/ja active Active
- 2017-12-04 KR KR1020197016015A patent/KR102655641B1/ko active Active
- 2017-12-04 AU AU2017372731A patent/AU2017372731B2/en active Active
- 2017-12-04 CA CA3045650A patent/CA3045650A1/en active Pending
- 2017-12-04 BR BR112019011661-3A patent/BR112019011661A2/pt unknown
- 2017-12-04 WO PCT/US2017/064561 patent/WO2018106615A2/en not_active Ceased
- 2017-12-04 CN CN201780084622.9A patent/CN110352247B/zh active Active
-
2023
- 2023-07-14 JP JP2023115763A patent/JP2023156294A/ja active Pending
- 2023-10-31 US US18/498,448 patent/US20240209379A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017372731B2 (en) | 2024-05-23 |
| US20240209379A1 (en) | 2024-06-27 |
| WO2018106615A2 (en) | 2018-06-14 |
| EP3548625A2 (en) | 2019-10-09 |
| CA3045650A1 (en) | 2018-06-14 |
| EP3548625C0 (en) | 2024-06-26 |
| AU2017372731A1 (en) | 2019-06-20 |
| JP7788787B2 (ja) | 2025-12-19 |
| KR102655641B1 (ko) | 2024-04-05 |
| US11845939B2 (en) | 2023-12-19 |
| KR20190134590A (ko) | 2019-12-04 |
| CN110352247B (zh) | 2024-06-28 |
| JP2023156294A (ja) | 2023-10-24 |
| CN110352247A (zh) | 2019-10-18 |
| US20180171340A1 (en) | 2018-06-21 |
| BR112019011661A2 (pt) | 2020-01-07 |
| EP3548625B1 (en) | 2024-06-26 |
| WO2018106615A3 (en) | 2018-08-09 |
| JP2020500536A (ja) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006467A (es) | Composiciones y métodos para mejorar la expresión génica. | |
| CL2019000167A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado. | |
| CL2020000937A1 (es) | Anticuerpo multiespecífico. | |
| MX2018015512A (es) | Tratamiento de dmre utilizando variante de aav2 con aflibercept. | |
| CL2018000587A1 (es) | Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017) | |
| MX2018007237A (es) | Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus. | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| CL2019000392A1 (es) | Métodos para detectar aav. | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| EA201890999A1 (ru) | Вакцина против вируса простого герпеса | |
| MX388331B (es) | Variantes de virus adenoasociado y métodos de uso de estas | |
| MX2016011686A (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| MX2019002938A (es) | Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih. | |
| AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX2016015952A (es) | Constructos de anticuerpo multiespecifico. | |
| MX2024009272A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| EA201691945A1 (ru) | Антитела к гемагглютинину вируса гриппа типа b и способы их применения | |
| EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| CL2018000164A1 (es) | Vector recombinante del virus orf. | |
| MX2016009149A (es) | Variantes mejoradas de enzimas. | |
| MX381844B (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: JANSSEN PHARMACEUTICALS, INC.* |